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Angioedema with acquired C1-inhibitor deficiency (C1-
INH-AAE) is a rare disease whose prevalence is estimated to 
be 1:500 000 [1]. Fewer than 200 cases have been reported in 
the literature. C1-INH-AAE manifests as recurrent episodes 
of nonpitting angioedema lasting 24-72 hours and involving 
mainly the face, tongue, uvula, and upper airways. Patients 
do not have a family history of angioedema, and onset of 
symptoms is usually after the age of 40 years [2]. 
The suspected diagnosis is confirmed by a C1-INH 
function <50% of normal. Moreover, C4 levels are reduced in 
almost all patients, and anti-C1-INH antibodies and low C1q 
plasma levels are detected in >70% of cases. C1-INH antigen 
levels are <50% in most patients, even if the presence of a 
cleaved form of C1-INH yielding apparently normal C1-INH 
protein levels is reported in 20% of patients [3,4].  
In some cases, it is difficult to differentiate C1-INH-AAE 
from idiopathic nonhistaminergic angioedema (InH-AAE). 
This condition comprises nonfamilial, nonhereditary forms 
in which known causes have been excluded and recurrences 
persist despite antihistamine treatment [5].
We report the case of a patient affected by recurrent 
angioedema with anti-C1-INH antibodies and normal C1-INH 
functional and antigen levels.
An 80-year-old woman came to our outpatient department in 
2011 because of recurrent attacks of angioedema without wheals. 
Her symptoms began in 2001 (aged 66 years) with an 
episode of peripheral edema without wheals or pruritus 
involving the upper arms and lasting 3 days. Shortly after 
onset, she experienced upper airway edema, which was treated 
with methylprednisolone 60 mg IV, chlorpheniramine 10 mg 
IM, ranitidine 50 mg IV, and epinephrine 0.5 mg IM, although 
no clear benefit was observed.
During the following years, she experienced angioedema 
without wheals that generally affected peripheral sites (about 
1 episode per month). The frequency of attacks decreased 
progressively until 2011, when she had a severe laryngeal 
attack requiring admission to the emergency department. 
The attack took 3 days to resolve, despite treatment with 
standard therapy for histaminergic angioedema including 
methylprednisolone, chlorpheniramine, and epinephrine.
The patient was subsequently referred to the Center for 
Diagnosis and Treatment of Angioedema at the University of 
Naples Federico II. Her past clinical history was unremarkable 
except for arterial hypertension, which had been treated with 
irbesartan and hydrochlorothiazide for about 1 year. None of 
her relatives had ever experienced angioedema. 
The patient underwent diagnostic tests, which excluded 
infection and autoimmune and allergic diseases. Since her 
history was typical of bradykinin-mediated angioedema, we 
measured levels of antigenic and functional C1-INH, C4, and 
C1q, all of which were normal. Nevertheless, because of her 
age and clinical history, we strongly suspected C1-INH-AAE. 
In some patients, at disease onset, C1-INH deficiency and 
consumption of complement components are only evident 
during angioedema attacks and not during the intercritical 
period. Therefore, we investigated anti-C1-INH antibodies 
using semiquantitative ELISA. We detected anti–C1-INH IgG 
in 2 subsequent determinations, but not anti-C1-INH IgM or 
IgA. Total serum IgG levels were within normal limits, thereby 
excluding false-positive results. Based on clinical data and 
on the presence of these antibodies, we classed this patient as 
C1-INH-AAE, that is, a patient at risk of lymphoproliferative 
disorders [6]. Consequently, she has since undergone tests 
every 6 to 8 months to rule out underlying autoimmune and 
lymphoproliferative diseases and monoclonal gammopathy of 
undetermined significance. 
Because her attacks were infrequent, we prescribed off-
label treatment with icatibant 30 mg SC on demand [7]. We 
trained the patient and her daughter to administer the drug; 
therefore, treatment was usually administered at home, 
except in 2 cases involving the upper airways, when she was 
treated with icatibant in the emergency department. To date, 
she has experienced 12 attacks involving peripheral sites or 
the upper airways and face. These attacks were treated with 
icatibant. Symptoms began to resolve after about 20 minutes 
and disappeared completely after 8-20 hours. In 1 case, the 
patient administered 2 syringes of icatibant for the same 
attack, possibly because she treated the attack more than 
6 hours after the onset of angioedema. No adverse events 
were reported.  
We evaluated complement components twice yearly 
during 3 years of follow-up, and values remained normal. 
Practitioner's Corner
J Investig Allergol Clin Immunol 2016; Vol. 26(2): 111-143 © 2016 Esmon Publicidad
  Manuscript received April 23, 2015; accepted for publication 
August 3, 2015. 
Maria Bova
Department of Translational Medical Sciences 
University of Naples Federico II
Via S. Pansini 5
IT–80131 Naples (Italy)
E-mail: bovamaria@virgilio.it
112
We recently retested the patient and confirmed the presence 
of anti-C1-INH IgG.
 A limitation in this case report is that C1-INH and C1q 
were never evaluated during the attacks [8]. However, C4 was 
measured during the only attack that required hospitalization 
and was found to be within the normal range. 
Given the patient’s clinical history and laboratory data, 
our diagnosis was InH-AAE with anti-C1-INH antibodies. 
Key features, including clinical presentation, age at onset, 
confirmed presence of anti-C1-INH antibodies, and response 
to icatibant, are reminiscent of C1-INH-AAE. However, the 
normal findings in the C1-INH functional assay and analysis 
of C4 and C1q do not allow us to confirm this diagnosis.
We propose 2 hypotheses to explain this unusual form 
of angioedema. First, the anti-C1-INH antibodies bind to 
C1-INH, leading to structural alteration of the molecule that 
precludes binding to factor XII without interfering in binding 
to C1 esterase, the substrate used for the functional assay of 
C1-INH activity [9]. Second, the case we report could be a 
true form of InH-AAE that responds to icatibant in which 
the presence of anti-C1-INH antibodies is no more than a 
concomitant laboratory finding with no pathogenic relevance.
We report a unique form of InH-AAE associated with 
anti-C1-INH antibodies that is clinically consistent with 
C1-INH-AAE. Our findings underline the importance of 
further investigating the role of anti-C1-INH antibodies in the 
pathogenesis of angioedema.
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The Siberian, Russian, or Dzungarian hamster (Phodopus 
sungorus) has gained great popularity with its introduction 
as a pet [1], probably because it is more sociable and smaller 
than other hamsters. The Siberian hamster (SH) has a similar 
appearance to common hamsters such as the European hamster 
(Cricetus cricetus) and the golden hamster (Mesocricetus 
auratus), although it belongs to a different genus. The fact that 
its main allergen shows no IgE cross-reactivity with allergens 
from European or golden hamsters [2] hampers diagnosis, 
because there is currently no standardized commercial extract 
available for SH. Clinical data on allergy to SH are relatively 
scarce [3-5]. We describe the clinical characteristics of patients 
sensitized to SH.
Consecutive patients from the outpatient clinic who had 
presented symptoms of allergy after exposure to SH were 
recruited from the outpatient clinic. All patients had kept at 
least 1 SH at home, mostly in cages, although the animals 
were free to run around the house. Most cases of allergy were 
caused by cleaning SH cages. Extracts were derived from 
hair, urine, and salivary glands and prepared as previously 
described [2]. 
Skin prick tests (SPT) with extracts of SH and a battery 
of common aeroallergens, including cat, dog, and horse 
extracts, were performed according to the guidelines of the 
European Academy of Allergy and Clinical Immunology 
Guidelines [6]. Five nonatopic patients were used as controls. 
Clinical assessments, spirometry, and fraction of exhaled 
nitric oxide (FeNO) measurements (NIOX MINO, Aerocrine, 
Sweden) were carried out at baseline and 6 months later, once 
the hamsters had been removed from the patients’ houses. 
Three patients underwent a specific nasal challenge (SNC) 
and two 2 types of specific bronchial challenge (SBC). All 
asthma medications, antihistamines, and nasal corticosteroids 
were withheld for at least 1 week before the start of a specific 
inhalation challenges. SNC was performed as previously 
described [7] using an extract of SH epithelium. The nasal 
response was monitored using a visual analog scale (VAS) 
for nasal congestion, sneezing, and rhinorrhea (recorded 
on a 100-mm line) and by acoustic rhinometry (SRE 2100; 
Rhino-Metrics). A decrease in minimal cross-sectional area 
(MCA), or Vol 5 ≥30% from baseline and an increase in any 
VAS parameters >20 mm were considered a positive test 
result [7,8]. A nasal smear was performed at baseline and 
24 hours after SNC [8]. One SBC was performed using the 
tidal volume method, as previously described [9]. The other 
challenge was carried out inside a 7- m3 inhalation challenge 
chamber. Four hamsters were placed inside a cage in the 
chamber. Airborne particles were measured using a DustTrak 
(TSI) aerosol monitor (mean, 0.130 mg/m3). FEV1 and nasal 
parameters were measured before exposure and every 10 
minutes during the first hour after challenge. FEV1 was then 
measured hourly until bedtime, upon awakening, and again the 
day after. A fall in FEV1 ≥20% from baseline was considered a 
positive asthmatic response. The methacholine challenge and 
induced sputum tests were performed as described elsewhere 
at baseline and 24 hours after exposure [10].
The statistical analysis was performed using the t test for 
dependent samples. Statistical significance was set at P<.05.
The study population comprised 21 SH-allergic patients, 
of whom 14 (66.7%) were female. The mean (SD) age was 
27.2 years (4.3; range, 10-46 years). Fifteen patients (71.42%) 
reported asthma and rhinoconjunctivitis symptoms while 
5 (23.81%) only reported rhinoconjunctivitis. One patient 
(4.76%) had experienced an anaphylactic reaction owing to 
an SH bite on a finger and required medical attention at the 
emergency department. The initial symptoms in most patients 
(71%) were respiratory symptoms 4 to 12 weeks after their 
first exposure to SH. Of note, 18 of the 21 patients (85.71%) 
had previously experienced respiratory symptoms as a result 
of sensitization to other pets, as follows: cat (10), dog (5), 
mouse (1), Guinea pig (1), and horse (1) (Table). All patients 
underwent SPT with these allergens. Eight patients (38.09%) 
required emergency treatment of asthma before diagnosis. 
Treatment at baseline is described in the Table. Medication 
was maintained until patients felt that their symptoms had 
improved.
The results of SPT were positive to all 3 SH extracts 
(epithelium, urine, and salivary glands) in all patients. Eleven 
patients (52.38%) were monosensitized to SH, while 8 
patients (38.09%) were also sensitized to Roborovsky hamster 
(Phodopus roborovskii) and 2 patients were sensitized to 
both SH and European hamster (Table). The results of SPT in 
control patients were all negative.
Statistically significant differences were observed in 
mean FEV1/FVC, FEV1, and FeNO values at baseline (FEV1/
FVC, 80.7 [9.8]; FEV1, 2.28 [0.62] L; FeNO, 49.52 [15.10] 
ppb) and after 6 months without exposure to SH (FEV1/FVC, 
86 [8.1]; FEV1, 2.72 [0.62] L; FeNO, 22.57 [8.27] ppb), 
(P<.0001). Treatment was also decreased in most patients 
(Table). Following the removal of the hamsters from their 
homes, 17 patients (80.95%) with SH allergy experienced an 
improvement in respiratory symptoms between weeks 4 and 
12, whereas 4 patients improved before week 4. 
Two patients presented intense rhinoconjunctivitis 
a few minutes after SNC and a decrease in MCA >30% 
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from baseline. Eosinophil counts in nasal smears increased 
significantly 24 hours after the SNC in both cases. SBC results 
were positive in 2 cases (1 early asthmatic reaction and 1 dual 
asthmatic response). An increase in FeNO values (30 vs 55 
ppb and 32 vs 45 ppb), an increase in sputum eosinophils (0.69 
vs 2.11 and 0.35 vs 2×106 L), and a significant decrease in 
methacholine PC20 (0.25 vs <0.125; 2.8 vs 0.6 mg/mL) were 
observed 24 hours after challenge.
In summary, exposure to SH in sensitized patients can elicit 
intense respiratory symptoms and even anaphylaxis if patients 
are bitten. The onset of symptoms was between 4 to 12 weeks 
after the initial exposure. The importance of avoiding exposure 
was demonstrated, since the patients reported here showed 
a clear improvement in symptoms, pulmonary function test 
results, and FeNO levels after removal of the SH from their 
homes. As we previously reported [2], it is important to use 
extracts of SH (urine, epithelium) to demonstrate specific IgE, 
since SH allergens have no cross-reactivity with European and 
golden hamsters.
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In recent years, an increasing number of aerobiological 
sampling stations have been installed in urban areas to report 
airborne pollen content. Several authors have studied the 
differences in atmospheric pollen levels between cities, which 
are mainly due to variations in local climatic and geographical 
conditions and to urban management [1,2]. Other studies in 2 
or more areas of the same city showed differences that were 
attributable to sampler height, variations in vertical movement 
of air [3], and surrounding vegetation [4].
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In the present study, we investigated the airborne 
pollen content of Salamanca (midwestern Iberian Peninsula 
[40º 58' N; 5º 40' W], Mediterranean continental climate, 800 m 
above sea level) by comparing 2 sampling stations located at 
different heights between February 1, 2007 and February 7, 
2008 (372 days). Our objective was to record potential 
differences in moderate and high pollen concentrations that 
could cause symptoms in sensitized people. 
Aerobiological samples were collected using 2 Hirst type 
volumetric pollen traps based on the impact principle [5]. 
Sampler 1, a Burkard 7-day recorder (Burkard Manufacturing 
Co Ltd) was placed on the roof of a centrally located 
municipal building 20 m above ground level. The immediate 
surroundings are characterized mainly by historical buildings 
and narrow streets with a low number of trees. Sampler 2, a 
VPPS 2000 (Lanzoni s.r.l.), was placed on the roof of the 
Faculty of Pharmacy at 30 m above ground level. The building 
is located on the outskirts of the city near the Tormes River and 
its riverside forests, 1.5 km west of the first location. 
Sampling, slide preparation, and data interpretation were 
all performed by the same person, who also recorded days with 
moderate and high pollen levels, following the criteria of the 
Spanish Aerobiology Network [6]. Total days with moderate 
and high levels in 2 samplers were obtained when at least 
1 type of pollen reached moderate and high concentrations. The 
Spearman rank correlation coefficient was used to establish 
the relationship between the daily pollen counts of both 
samplers. This test was chosen because daily pollen counts 
are not normally distributed. Statistical analysis was carried 
out using SPSS Version 12.0.
Table. Aerobiological Data From 2 Samplers During the Study Period and Spearman Rank Correlation Coefficients for Comparison of Levels of the Main 
Pollen Types 
   Sampler 1    Sampler 2   Spearman
 Total Peak Peak Days With Total Peak Peak Days With Correlation 
 Pollen Valuea Day Moderate/High  Pollen Valuea Day Moderate/High Coefficientb 
    Levels    Levels 
Total 31 478 957 June 8 106 28 493 959 March 10 100 0.939
Quercus 9352 689 June 6 38 8368 551 May 13 38 0.845
Poaceae 7764 355 June 30 72 6932 282 June 30 73 0.902
Cupressaceae 4047 550 March 4 26 3728 853 March 10 15 0.700
Plantago 1706 159 July 13 16 1437 106 May 10 13 0.860
Populus 1087 180 March 19 4 1465 322 March 13 6 0.935
Platanus 1017 297 April 16 5 751 117 March 19 7 0.789
Rumex 1012 52 May 11  10 1031 58 May 11 10 0.847
Urticaceae 969 31 June 23 9 950 43 April 29 9 0.799
Olea 678 162 June 8 2 525 107 June 8 2 0.660
Fraxinus 425 51 February 16 1 504 53 March 10  1 0.759
Castanea 410 62 July 8 2 374 60 July 8 1 0.843
Pinus 686 79 June 5 1 236 42 June 6 0 0.646
aPollen grains/m3
bP<.01.
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The total number of airborne pollen grains counted during 
the 372 study days was higher in sampler 1 than in sampler 
2 (64 and 61 types of pollen, respectively). Boraginaceae, 
Pittosporum, Scrophulariaceae, Sophora, and Thymelaeaceae 
grains were not found in sampler 2, and Convolvulus, Medicago, 
and Philadelphus grains were not found in sampler 1. The main 
types of pollen in both samplers were Quercus, Poaceae, 
and Cupressaceae, which together accounted for 67% of the 
total pollen levels recorded. Sampler 1 showed higher total 
pollen levels and higher peak values for all but 18 pollen 
types (mainly Populus, Fraxinus, Rumex and Ericaceae). 
Levels of Cupressaceae pollen grains were higher in sampler 
1, although their maximum daily concentration was higher in 
sampler 2. With respect to the moderate and high daily levels 
reported for the main pollen types, sampler 1 revealed more 
days with moderate and high levels in most cases, except for 
Poaceae, Populus, and Platanus, for which moderate and high 
levels were observed on more days in sampler 2 (Table). The 
number of days with high levels for Fraxinus, Olea, Rumex, 
and Urticaceae was the same for both samplers.
The Spearman rank correlation coefficient revealed high 
correlations between the total daily counts of the 2 sampling 
sites, with significant values (P<.01) for the main types of 
pollen.
Knowledge of atmospheric pollen levels can improve 
the diagnosis and treatment of pollen allergy. Another study 
conducted in the same area showed that sensitization was 
most frequent to Poaceae, followed by Olea, Cupressaceae, 
Plantago, Artemisia, and Platanus [7]. Few differences were 
obtained after comparison of the 2 samplers, revealing a 
close statistical correlation between them, as reported in other 
southern European cities [8,9]. Small variations recorded in 
the occurrence of peak days in both samplers and even lower 
correlation coefficients in some pollen types during the study 
period could be due to differences in the distribution of urban 
flora throughout the city. In addition, local differences in the 
timing of the peak could be significant for some people with 
pollen allergy [10]. Our results indicate that 1 volumetric 
sampler is sufficient to record the main airborne pollen types, 
their atmospheric behavior, and daily high levels in an urban 
area.
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Food protein–induced enterocolitis syndrome (FPIES) is a 
non–IgE-mediated food hypersensitivity reaction characterized 
by profuse, repetitive vomiting and diarrhea that may progress 
to dehydration and shock in 15%-20% of patients. FPIES is 
usually caused by cow’s milk or soy in formula-fed infants 
whose food contains solids, rice, oat, barley, chicken, turkey, 
fish, and, rarely, peanut [1]. Case series and reports of FPIES 
with hen’s egg have been triggered by both egg white and 
yolk [2]. The prevalence of egg allergy is estimated to be 
between 1.8% and 2% in children younger than 5 years of 
age [3]. Allergy to quail’s egg is a rare condition described 
only in case reports [4,5]. 
We report the case of a 3-year-old girl with no history of 
food allergy who was brought to hospital with repetitive and 
persistent vomiting, abundant bloody diarrhea, and systemic 
hypotension (60/40 mmHg). She was severely dehydrated. Stool 
analysis revealed a high red blood cell count. The complete 
blood count disclosed the following: hemoglobin, 15.7 g/dL; 
erythrocytes, 5.6×106/µL; white blood cells, 27 650/µL; and 
platelets, 400 000/µL. No pathogenic bacteria were detected 
in the stool culture. The patient was discharged after recovery. 
One week later, she was admitted with the same symptoms, 
which started 2 hours after consumption of boiled quail’s egg 
on “quail’s egg day” in her kindergarten. She had no other food 
allergy or any known allergic disease before attending the school 
and had never consumed quail’s egg.  
Skin prick tests for foods (cereals, hazelnut, peanut, 
walnut, cacao, tuna fish, chicken, banana, strawberry, 
tomato, hen’s egg, and cow's milk) were performed using 
commercial extracts (Stallergènes). Positive and negative 
controls (histamine and saline) were also applied. The result 
was negative for all allergens, including hen’s egg. The results 
of prick-to-prick testing with uncooked and boiled yolk and 
white of quail’s egg were negative. Serum specific IgE for 
hen’s egg was negative. An oral challenge with quail’s egg 
was performed starting at 1 g. Two hours later, the patient 
began to vomit repetitively. After 4 hours, she had bloody 
diarrhea. None of the symptoms recurred when quail’s egg was 
eliminated from her diet during the 1-year follow-up period. 
The patient tolerates hen’s egg.
We present an unusual case of severe quail's egg protein–
induced enterocolitis in a hen’s egg–tolerant 35-month old girl 
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who was admitted with hypotension, recurrent vomiting, and 
abundant bloody diarrhea. To our knowledge, this is the first 
report of life-threatening quail's egg–induced enterocolitis.
Domestic hen (Gallus domesticus) and quail (Coturnix 
coturnix) belong to the family Galliformes. The 5 major 
allergens identified in hen’s egg are ovomucoid (Gal d 1), 
ovalbumin (Gal d 2), ovotransferrin (Gal d 3), lysozyme 
(Gal d 4), and albumin (Gal d 5). Most allergenic proteins 
are contained in egg white (Gal d 1-4) rather than egg yolk 
(Gal d 5). Ovomucoid is resistant to degeneration by heat 
and digestive enzymes, thus making it the most allergenic 
protein, whereas ovalbumin is the most abundant protein [6]. 
Although clinical and serological cross reactivity between 
hen’s egg protein and proteins of eggs from other birds has 
been described for IgE-mediated food reactions [7], there 
is no such description for non–IgE-mediated food reactions 
including FPIES. IgE-mediated allergy with allergy to other 
bird’s eggs in the absence of IgE-mediated hen’s egg allergy 
has been reported [8].
Data from 2 cohorts of 168 and 38 children with FPIES 
revealed hen’s egg–induced FPIES in 3 and 4 children, 
respectively [9,2], while in a retrospective study [10], egg was 
found to be the fifth most commonly involved food in FPIES 
and responsible for 11% of cases. Onset of FPIES can occur 
a few days after birth up to 1 year, and the condition usually 
resolves by 2-3 years of age [6]. In our case, the patient was 
35 months old at diagnosis and had consumed quail’s egg 
relatively late. In a report of 4 cases of FPIES with hen’s egg, 
one patient was 48 months old when the initial symptoms 
started and 54 months at diagnosis [2].  
Both determination of specific IgE and skin prick tests 
are useful for diagnosing IgE-mediated egg allergy, although 
these approaches have no role in the diagnosis of non–IgE-
mediated egg allergy. A complete clinical history is paramount, 
and an oral food challenge is necessary for confirmation [6]. 
In support of these observations, in the case we report, the 
results of prick tests were all negative including tests with 
quail’s egg and hen’s egg, and the oral food challenge with 
quail’s egg triggered symptoms of enterocolitis. Quail’s egg 
was eliminated from the patient’s diet, and the symptoms did 
not recur during 1 year of follow-up.
To our knowledge, this is the first report of life-threatening 
FPIES triggered by quail’s egg. Diagnosis was early. As hen’s 
egg–induced FPIES is increasingly reported in the literature, 
other bird’s eggs should be borne in mind, even if no symptoms 
are detected with ingestion of hen’s egg. Although FPIES is 
mostly seen below 1 year of age, in older children presenting 
with symptoms such as vomiting, bloody diarrhea, and 
hypotension of unknown cause, a complete clinical history 
should be taken to record initiation of symptoms after specific 
food ingestion and thus rule out allergic etiologies.
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Drug-induced hypersensitivity syndrome (DIHS), also 
known as drug reaction with eosinophilia and systemic 
symptoms (DRESS), is a rare but severe clinical entity that 
requires early withdrawal of the causative agent. A high degree 
of diagnostic suspicion is needed. Several diagnostic criteria 
have been established based mainly on clinical features, 
laboratory findings, and the association between administration 
of the culprit drug and onset of the reaction. The etiologic 
diagnosis is difficult (many drugs may be involved), the result 
of the allergy workup is usually negative, and a challenge 
test is not advisable owing to potentially life-threatening 
consequences. We present a case of isoniazid-induced DRESS 
in which the culprit agent was identified by positive results 
in an intradermal skin test (IDT, delayed reading), patch test, 
and lymphocyte transformation test (LTT).
A 21-year-old Peruvian man with pulmonary tuberculosis 
started treatment with ethambutol, isoniazid, pyrazinamide, 
and rifampicin. He was admitted 1 month later with fever, 
lymphadenopathy, pruritic rash, facial edema, leukocytosis 
(40 600/mm3), atypical lymphocytosis (13 800/mm3), elevated 
liver enzyme levels (aspartate aminotransferase, 664 U/L; 
alanine aminotransferase, 637 U/L), and dyspnea. A few days 
later, he experienced respiratory failure and required invasive 
mechanical ventilation in the intensive care unit. Fine-cut 
computed tomography scans showed features compatible 
with alveolitis, and skin biopsy revealed mild superficial 
perivascular dermatitis with the presence of eosinophils. 
The results of serological tests (for respiratory tract and liver 
infections and viral infections [human immunodeficiency 
virus, herpes]) and autoimmunity studies were negative.  
Despite discontinuation of the antituberculosis drugs, the 
patient’s condition worsened, and systemic corticosteroids 
and second-line antituberculosis therapy (ethambutol, 
streptomycin, and levofloxacin) were started. Three weeks 
later, the patient’s symptoms resolved, and his pulmonologist 
reintroduced rifampicin cautiously. No adverse events were 
recorded.
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Figure. Positive patch test with isoniazid at 96 hours.
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The allergy workup, which was performed 8 months after the 
onset of symptoms, included skin tests (prick test and IDT with 
immediate and delayed readings) with isoniazid and pyrazinamide 
(isoniazid, prick [60 mg/mL] and IDT [0.6 mg/mL]; pyrazinamide, 
prick as is), patch tests (TRUE Test with solutions of isoniazid 
1% in water and pyrazinamide 1% in alcohol), and LTT 
with isoniazid and pyrazinamide. Tests were positive with 
isoniazid (delayed IDT test at 72 hours, which remained 
positive until day 7; patch test [+++] at 96 hours; and LTT at all 
concentrations tested [1, 5, 10, 50, and 100 mg/mL]) (Figure). 
The result of the oral challenge test with pyrazinamide was 
negative. 
The diagnosis of DRESS remains mainly clinical [1]. 
The 2 sets of diagnostic criteria usually adopted are those 
of the International Registry of Severe Cutaneous Adverse 
Reactions group and the Japanese consensus group [2,3]. The 
case discussed here fulfills both sets of criteria. 
We present the case of a patient who experienced isoniazid-
induced DRESS with positive results in in vivo and in vitro 
tests. Isoniazid is a very rare cause of DRESS [4-7]. In the 
case we report, both the patch test and LTT were helpful in the 
diagnosis of DRESS, in which many drugs are implicated [6,8]. 
Nevertheless, physicians should be aware of the possibility of 
life-threatening drug reactions associated with patch testing 
in DRESS [9]. LTT, an ex vivo technique, seems to be safer, 
although further studies are needed to establish its sensitivity 
and specificity, especially in patients with serious conditions, 
such as DRESS. 
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Methacholine challenge testing is a key tool in the 
evaluation and management of asthma [1], and several 
protocols are currently available [2,3]. Given that the cost-
effectiveness of these protocols has received little attention, 
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our objective was to compare the effectiveness and cost of 
3 common methods of methacholine bronchial challenge.
We evaluated consecutive patients referred to our center for 
methacholine bronchial challenge owing to suspected asthma 
in 3 time periods. According to current guidelines, bronchial 
challenge was performed by the pulmonologist or allergist who 
attended the patient, and all participants signed the informed 
consent document. 
Between 1992 and 1996, we used the 5-breath protocol of 
Chai et al [4]. Methacholine was diluted in phenol-buffered 
saline and administered using a continuous jet nebulizer. 
In each successive stage, 5 puffs of methacholine were 
administered (from 0.0625 to 16 mg/dL of solution) [4]. 
Spirometry was performed 5 minutes after each dose, and 
the result was considered positive when FEV1 fell by ≥20%. 
In 2000 and 2001, the technique used was the long protocol 
of the dosimetric method of Chinn et al [5] and, subsequently, 
García Río et al [6], while in 2013 and 2014 the technique used 
was the simplified protocol of the dosimetric method [5], which 
was later amplified by Perpiñá et al [3]. The difference between 
the methods lies in the number of doses administered, namely, 
9 in the long protocol and 5 in the simplified protocol. A 
Table, A. General Characteristics of the Study Patients 
  Five-Breath  Long Protocol of the Simplified Protocol of the P Value 
  Methoda Chinn Dosimeter Methodb Chinn Dosimeter Methodc
Time period 1992-1996 2000-2001 2013-2014 -
No. 1276 245 303 -
Gender    .396 
 Women, % 63.3 62.9 62.7  
 Men, % 36.7 37.1 37.3 
Age, y 32 (15) 36 (18) 38 (15) .081
Height, cm 162 (9) 163 (9) 163 (10) .625
Weight, kg 73 (14) 74 (13) 72 (15) .539
BMI, kg/m2 28.1 (5.4) 27.8 (6.3) 27.7 (5.9) .368
Current smokers, % 26 22.0 20.8 .352
Baseline FVC, L 3.50 (1.03) 3.47 (0.98) 3.50 (1.04) .369
Baseline FVC, % predicted 105 (14) 105 (15 106 (17) .249
Baseline FEV1, L 2.50 (0.87) 2.46 (0.89) 2.47 (0.82) .317
Baseline FEV1, % predicted 99 (12) 97 (5) 100 (15 .366
Baseline FEV1/FVC  0.80 (0.06) 0.78 (0.04) 0.79 (0.06) .631
Asthma suspicion by     .344 
 Wheezing, % 58.2 53.1 57.1  
 Persistent cough, % 22.5 24.5 24.2  
 Previous AHR, % 12.4 14.7 12.2  
 Dyspnea, % 6.9 7.8 6.3 
Maximum fall in FEV1, % 16.5 (18.4) 14.0 (11.8) 14.2 (10.5) .272
Severity of AHR     .103 
 Mild, % - 63.7 73.6  
 Moderate-severe, % - 36.3 24.3
Abbreviations: BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; AHR, airway 
hyperresponsiveness.
aChai et al [4].
bChinn et al [5,6].
cChinn et al [3,5].
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Table, B. Cost Analysis of the Methacholine Challenge Tests Evaluated 
Protocol Five-Breath  Long Protocol of the Simplified Protocol 
  Methoda Chinn Dosimeter Methodb of the Chinn Dosimeter Methodc
Period 1992-1996 2000-2001 2013-2014
Estimated working time and methacholine consumption
Test duration, min  90  120  80 
No. scheduled test/day 1 2 3
Physician, min 28 min (prior rating, 5 min;  32 min (prior rating, 5 min; 24 min (prior rating, 5 min; 
  availability during the test  availability during the test availability during the test 
  [20% of the time]:,18 min;  [20% of the time], 24 min; [20% of the time], 16 min; 
  report, 5 min) report, 3 min)  report, 3 min)
Pharmacist, min 0.75 min (build 5 + 1 vials 4 weeks,  0.75 min (prepare 9 + 1 vials 0.16 min (prepare 3 + 1 vials 
  15 min; 1 test/day, 20 days = 20 tests,  4 weeks, 30 minutes; 2 tests/day, 4 weeks, 10 min; 3 tests/day, 
  15/20 = 0.75 min per test) 20 days = 40 tests,  20 days = 60 tests, 
   30/40 = 0.75 min per test) 10/60 = 0.16 min per test).
Nurse, min 86 min (explain procedure, 3 min;  113 min (explain procedure, 3 min; 74 min (explain procedure, 
  puffs  [5 + 1], 12 min; standby time  puffs [9 + 1], 10 min;  3 min; puffs [5 + 1], 6 min; 
  [5 + 1], 18 min; spirometry [7], 35 min;  standby time [9 + 1], 20 min; standby time [5 + 1], 12 min; 
  bronchodilator and spirometry, 15 min;  spirometry [11], 55 min; spirometry [7], 35 min; 
  observation, 3 min) bronchodilator  and spirometry, bronchodilator  and spirometry, 
   15 min; observation, 10 min)  15 min; observation: 3 min)
Nursing assistant,  19 min (measurement of height  24 min (measurement of height 13 min (measurement of 
min and weight, 3 min; place  and weight, 3 min; place height and weight, 3 min; 
  mouthpiece and filter, 1 min;   mouthpiece and filter, 1 min;  place mouthpiece and 
  solutions management, 10 min;   solutions management, 10 min;  filter, 1 min; solutions 
  cleaning equipment, 5 min) cleaning equipment, 10 min) management, 5 min;   
    cleaning equipment, 4 min)
Secretary, min 7 min (appointment and copy report)  2 min (appointment) 2 min (appointment)
Volume of the solutions  
prepared with  
1 methacholine vial, mL 9 3 12
Reqired solutions volume, mL 2.5 4.5 2.5
Used methacholine vials 0.28 1.5 0.21
Cost of methacholine €15.00 €80.50  €11.30 
Cost analysis
Personnel cost 
 Physician (€0.55/min) 15.40 17.60 13.20 
 Pharmacist (€0.55/min) 0.41 0.41 0.09 
 Nurse (€0.36/min) 30.96 40.68 26.64 
 Nursing assistant (€0.27/min) 5.13 6.48 3.51 
 Secretary (€0.27/min) 1.89 0.54 0.54 
 TOTAL 53.79 65.71 43.98
Material/equipment Cost 
 Equipment amortization €5.22 (230 studies €3.91 (460 studies €2.61 (690 studies 
  per year × 5 years = 1150  per year × 5 years = 2300 per year × 5 years = 3450 
  possible feasibility studies;  possible feasibility studies; possible feasibility studies; 
  equipment cost = €6000;  equipment cost = €9000; equipment cost = €9000; 
  €6000/1150 studies = €5.22 p €9000/2300 studies = €3.91 €9000/3450 studies = €2.61  
  per test) per test) per test) 
 Amortization of material  €0.09 €0.08 €0.03 
 (tweezers, nebulizers) (€100/1150 studies) (€180/2300 studies) (€100/3450 studies) 
 Consumables €0.45 (mouthpiece/filter) €0.45 (mouthpiece/filter) €0.45 (mouthpiece/filter) 
 Methacholine vials cost  €15.00 €80.50 €11.30 
 TOTAL €20.76 €84.94 €14.39
General cost (water, electricity,  
laundry, maintenance,  
property expenses)d €11.25  (90 min × € 0.125) €15 (120 min × €0.125] €10 (80 min ×  €0.125)
TOTAL €85.80  €165.65  €68.37 
Methacholine challenge test results
N  1276 245 303
Positive challenge, % 33.0 31.4 34.0
PD20, mg 47 (34) CU 0.702 (0.681) 0.807 (0.567)
aChai et al [4]. bChinn et al [5,6]. cChinn et al [3,5]. d€64 827 per year (minus staff costs) = €64 827/12 = €5402 per month; €5402/43 200 min in a month 
= €0.125 per minute
122
Practitioner's Corner
J Investig Allergol Clin Immunol 2016; Vol. 26(2): 111-143© 2016 Esmon Publicidad
dosimeter (APS, Viasys) was used in both cases to nebulize the 
doses of methacholine that correspond to each step. Spirometry 
was performed 90-120 seconds after each nebulization, and the 
test was interrupted if a fall in FEV1 ≥20% was recorded. In 
both cases, the PD20 (dose which causes a 20% fall in FEV1) 
was determined [3].
Costs were estimated taking into account the duration of 
the protocol, which was based on data from daily practice 
(considering the average time to perform at least 20 tests 
and the distribution of responsibilities between the health 
professionals from our center). The Table shows the test 
duration and timing of the tasks assigned to the physician, 
pharmacist, nurse, nursing assistant, and secretary at the 
completion of each challenge test according to the different 
protocols evaluated. Secretary times are lower in the dosimetric 
method [3,5,6] than in the 5-breath method [4], since the 
report is automatically generated. Given these working times, 
wage costs were determined directly from the salaries of 
personnel assigned to our laboratory in 2013. According to 
data provided by the Analytical Accounting Service of our 
center and taking into account that the working week in our 
autonomous community was 37.5 hours, with 46 weeks per 
year, it was estimated that the cost per minute of the physician, 
nurse, nursing assistant/administrative personnel was €0.55, 
€0.36, and €0.27, respectively. 
The number of vials of methacholine used in each protocol 
was calculated based on the volume of methacholine solution 
that can be prepared from a vial and the volume of solution 
required. As the current price of 6 vials of methacholine 
(Provocholine) amounts to €321.99, the purchase cost of 
methacholine was determined. Moreover, the amortization 
of consumables and lung function testing equipment was 
estimated for the medium term and according to the market 
price. Finally, general costs (eg, water, electricity, laundry, 
maintenance, electricity, and property expenses) were 
established according to the report made in 2013 to our hospital 
functional group by the Analytical Accounting Service.
We evaluated 1824 patients (1276 in the first period, 245 
in the second, and 303 in the third), with a predominance 
of women in all groups. No differences in anthropometric 
characteristics, smoking habit, baseline lung function, or 
indications for bronchial challenge were detected between 
the 3 periods analyzed. Similarly, the minimum FEV1 reached 
after the methacholine bronchial challenge was similar across 
the 3 periods. No differences in PD20 or severity of airway 
hyperresponsiveness were detected between the long and short 
protocols of the dosimetric method [3,5,6] (Table, A).
Personnel costs were higher in the long protocol 
(€65.71) than in the simplified protocol (€43.98) (Table, B). 
Similarly, the simplified protocol had the lowest expenses for 
consumables and amortization of equipment (€14.39) and 
general costs (€10.00), whereas the long protocol consumed 
more resources (€84.94 and €15.00, respectively). The 
estimated total costs were €85.80 for the 5-breath method, 
€165.70 for the long protocol, and €68.40 for the simplified 
protocol.
Based on the number of challenge tests necessary to obtain 
a positive result, the cost of a positive test was lower for the 
simplified protocol (€198.30) than for the 5-breath method 
and the long protocol (€260.00 and €530.10, respectively).
To our knowledge, the only previous estimation of the 
costs of methacholine challenge testing was performed by the 
Centers for Medicare and Medicaid Services, who assigned a 
reimbursement of €147.50 for each test [7]. Our data show that 
costs vary considerably depending on the method chosen. While 
the long protocol exceeds this amount (€165.65), the costs of the 
5-breath method and the simplified protocol are substantially 
lower. In fact, using the simplified protocol enables more than 
half of the expected costs to be saved (€68.37). 
The costs generated by methacholine challenge testing 
must be interpreted in the context of global asthma costs, 
particularly in patients with poorly controlled asthma, which 
generates the highest consumption of resources. In Spain, 
up to 70% of the overall asthma cost is attributed to poor 
control, and the annual cost of the use of medical resources 
in patients with poorly controlled asthma has been reported 
to amount to €1451.30 [8]. In this situation, the cost of the 
methacholine challenge test seems acceptable, especially if 
we take into consideration the importance of identifying and 
characterizing the disease, the association with quality of life, 
and the potential ability to monitor treatment [9,10].
In conclusion, our results show that performing the 
methacholine challenge test using the simplified protocol of 
the dosimetric method [3,5] is more cost-effective than the 
long protocol of the same method and the 5-breath method of 
Chai et al [4]. Therefore, it should be considered the preferred 
approach, both for diagnosis of patients with suspected asthma 
and to ensure better disease control.
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Drug reaction with eosinophilia and systemic symptoms 
(DRESS) is a rare, severe, acute, drug-induced hypersensitivity 
reaction that includes skin eruption, hematologic abnormalities, 
lymphadenopathy, and internal organ involvement [1]. 
Given the variability of the clinical picture, the diagnosis 
of DRESS is based on the accountability score proposed 
by Kardaun et al [2]. Rivaroxaban (Xarelto) is a new oral 
anticoagulant (factor Xa inhibitor) indicated for prevention of 
venous thromboembolism in adults after elective hip or knee 
replacement surgery. We report a case of rivaroxaban-induced 
DRESS occurring 10 days after initiation of therapy. 
A 65-year-old man who had been receiving long-term 
treatment with atorvastatin and Serenoa repens underwent hip 
prosthesis surgery and was treated with rivaroxaban (10 mg, 
1 tablet per day) for prophylaxis of thrombophlebitis starting 
on the day of discharge from hospital, 1 week after surgery. 
Ten days later, he began to experience chills with fever 
that persisted and rose to 40.5°C followed by generalized 
skin erythema with pruritus on day 15. He was admitted 
to hospital on day 18 to undergo a series of investigations. 
The chest x-ray showed a discreet bilateral pulmonary 
infiltrate. The findings of venous ultrasound of the lower 
limbs and abdominal ultrasound examination were normal. 
Blood and urine cultures were negative. The patient received 
histamine H1 antagonists and was discharged from hospital. 
Rivaroxaban was administered until day 20. Forty-four hours 
after discontinuation of rivaroxaban, the patient was admitted 
to the intensive care unit with hypotension and bradycardia. 
At admission, he had anemia, elevated white blood cell 
count with increased neutrophils and eosinophils, acute 
renal failure (filtration rate 45 mL/min) with no proteinuria, 
and mild cholestasis. Levels of alanine aminotransferase, 
gamma-glutyamyl transpeptidase, and direct bilirubin were 
increased, and prothrombin time was prolonged. Arterial 
blood gas analysis revealed hypoxia. The patient was 
treated with intravenous fluids and atropine. A computed 
tomography scan of the chest showed bilateral pulmonary 
infiltrates suggestive of alveolitis, marked thickening of the 
perilobular interstitium, marked peribronchovascular edema, 
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of oral corticosteroids at 0.5 mg/day. He underwent subsequent 
corticosteroid tapering over 3 months, with no recurrence once 
the regimen was complete. 
DRESS is a severe, idiosyncratic reaction that 
characteristically arises within 1-8 weeks after exposure to the 
culprit drug. In the case we report, the reaction began 10 days 
after initiation of rivaroxaban. The clinical features included 
cutaneous eruption, fever, multiple lymphadenopathies, 
hematological abnormalities (most often eosinophilia), and 
visceral involvement (ie, hepatitis, interstitial nephritis, and 
pneumonitis). The initial symptoms in the present case were 
fever and skin eruption 10 days after exposure to the drug. 
Hepatitis is common (60%-80%), although kidney and lung 
involvement are less common (10%-30% and 5%-25%, 
respectively) [3]. The laboratory abnormalities in the present 
case included elevated white blood cell count with increased 
eosinophils, acute renal failure, and mild cholestasis. All the 
alternative diagnoses were ruled out through negative results 
in viral, bacterial, and immunological examinations.
In order to help clinicians confirm the diagnosis of DRESS, 
the European Registry of Severe Cutaneous Adverse Reactions 
(RegiSCAR) devised a scoring system based on clinical 
features, extent of skin involvement, organ involvement, and 
clinical course [4]. RegiSCAR proposes a series of criteria 
for DRESS, according to which hospitalized patients with 
drug rash must have at least 3 of 4 systemic features (fever, 
lymphadenopathy, internal organ involvement, hematological 
abnormalities). In the present report, our patient developed 
all 4 criteria of the DRESS syndrome, and the Kardaun score 
was 6 (certain) [3]. 
Identification and prompt withdrawal of the offending 
drug is the mainstay of treatment for patients with DRESS. 
Although optimum treatment remains controversial, patients 
are usually treated with corticosteroids [1].
DRESS is most commonly induced by antiepileptic agents 
(sulfonamides) [5] and rarely by anticoagulants [6,7]. Patch 
tests have proven useful for identification of the causative drug 
when patients are receiving several drugs simultaneously [7]. 
However, the diagnostic value of patch testing remains unclear, 
and the results of patch testing vary significantly depending 
on the specific drug. Patch tests appear to be most reliable for 
antiepileptic medications or proton pump inhibitors but remain 
negative in testing with allopurinol or sulfasalazine [8,9]. In the 
present case report, patch tests were not applied, as rivaroxaban 
was the only causative drug that could be identified. Indeed, the 
patient’s regular treatment (atorvastatin and Serenoa repens) 
had been continued, and the patient had not taken other drugs 
that were discontinued for fewer than 14 days before onset. 
We describe a clinical observation of rivaroxaban-induced 
DRESS. The clinical course was favorable, with progressive 
regression of symptoms after initiation of corticosteroids.
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and multiple mediastinal lymphadenopathies (Figure, A). 
The abdominopelvic computed tomography scan showed 
lumbar lymphadenopathy and a bilateral perirenal infiltrate 
(Figure, B). Peripheral eosinophilia peaked at 1065/mm3 the 
following day. The clinical course after circulatory stabilization 
was favorable, but the patient had persistent low-grade fever 
(38.2°C) and rash on the lower limbs for several days. A 
series of tests were performed to rule out other differential 
diagnoses, as follows: protein electrophoresis; measurement of 
ferritin; assessment of thyroid hormones; immunological tests; 
viral serology tests (hepatitis, cytomegalovirus, Epstein-Barr 
virus, parvovirus B19, and human immunodeficiency virus); 
serology of Lyme disease, mycoplasma, and chlamydia; and 
the urinary antigen test for the diagnosis of pneumococcal 
pneumonia and Legionella urinary antigens. Blood and urine 
cultures were also negative.
Given the severity of the clinical presentation and 
the associated unexplained prolonged high fever, rash, 
eosinophilia, pulmonary infiltrates, acute renal failure, multiple 
lymphadenopathies, and abnormal liver function, a diagnosis 
of DRESS was proposed. The Kardaun score was 6, which 
indicates DRESS with a high degree of certainty. The patient 
was discharged from the intensive care unit after introduction 
Figure. Chest (A) and abdominopelvic (B) computed tomography scan 
showing bilateral pulmonary infiltrates suggestive of alveolitis, marked 
thickening of the perilobular interstitium, marked peribronchovascular 
edema, multiple mediastinal and lumbar lymphadenopathies, and a 
bilateral perirenal infiltrate.
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Asthma is the most common chronic respiratory disease 
in children [1]. Atopy is an important risk factor in the onset, 
persistence, and severity of asthma, and sensitization to 
aeroallergens has been demonstrated in more than 80% of 
asthmatic children [2]. Consequently, the role of allergists in 
the correct diagnosis, treatment, and follow-up of pediatric 
asthma is decisive.
Assessment of lung function and bronchial inflammation 
are key components in the diagnostic workup and follow-up 
of allergic respiratory diseases, including asthma [3]. Even 
young children can perform many of the tests used and benefit 
from them [4]. However, the availability of tests and expertise 
in using them among allergists are unknown.
We designed an electronic mail–based survey that was 
sent to the allergy departments of Spanish tertiary teaching 
hospitals. We questioned health professionals on their 
knowledge of the main physiologic and inflammatory tests 
(spirometry, bronchodilator test, plethysmography, impulse 
oscillometry, exercise test, challenge tests [mannitol, 
methacholine, adenosine], specific bronchial challenge, 
exhaled nitric oxide [eNO], and induced sputum) and the 
availability of these tests in their institutions. We also recorded 
the age of the patients attended (>18 years, >14 years, all ages).
In order to quantify experience with each test, we analyzed 
the frequency with which they were used for clinical or 
research purposes. Therefore, experience was classified as 
scarce, medium, and broad. 
Experience with spirometry and/or eNO in children 
was considered scarce if <5 tests per day were performed; 
broad experience was defined as >10 tests per day. For the 
bronchodilator test, experience was considered scarce if <3 
tests per day were performed; broad experience was defined as 
>5 tests per day. As for exercise, mannitol, and methacholine 
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challenge tests, <3 tests per month was considered scarce 
experience, whereas >5 tests was considered broad experience. 
Experience with the least used and least indicated tests in 
children (ie, plethysmography, oscillometry, adenosine 
challenge, specific bronchial challenge, and/or induced 
sputum) was considered scarce if the tests were performed 
<5 times per year and broad if they were performed >10 
times per year. Intermediate frequencies indicated medium 
experience. 
Replies were received from 38 of the 42 centers surveyed. 
Eleven were rejected, as the patients attended were aged 
>18 years. Of the 27 valid surveys, 2 were from centers that 
attended patients >14 years, and the remaining 25 were from 
centers that attended patients of all ages. 
The results for lung function, bronchial hyperresponsiveness, 
and inflammatory tests are shown in the Table.
With respect to lung function tests, surprisingly, experience 
in basic tests such as spirometry was broad in only one-
third of tertiary hospitals. In contrast, almost half of them 
had scarce experience. Similar results were obtained with 
the bronchodilator test. Although plethysmography and 
oscillometry were infrequent, the few centers that did perform 
them reported broad experience.
Of the bronchial hyperresponsiveness tests available, 
exercise and specific bronchial challenge were used 
extensively, despite their limited indication in children. On 
the other hand, mannitol and/or methacholine challenge 
tests were rarely applied in routine practice. Only 2 centers 
claimed to have wide experience in these techniques, even 
though the methacholine challenge test is the most sensitive 
test for studying bronchial hyperresponsiveness and is clearly 
indicated in the diagnosis of pediatric asthma [5]. 
Bronchial inflammation is underanalyzed in children, 
as most of the centers surveyed admitted having scarce 
experience in eNO in daily clinical practice, even though this 
is a noninvasive and easy test for analysis of inflammation in 
asthma [6].
Many studies analyze education of asthmatic patients by 
surveying the patients themselves [7]. Despite the importance 
of specialist training, very few studies analyze knowledge of 
asthma among pediatricians [8], compare the knowledge of 
physicians and specialists [9], or even analyze differences in 
asthma management between respiratory specialists such as 
pulmonologists and allergists [10]. No self-critical reports 
have been made to date regarding the evaluation of asthma 
knowledge among specialists. 
Experience with and availability of pediatric lung function 
testing and/or inflammatory tests must be promoted among 
allergists. The poor results obtained can be explained mainly 
by the inadequacy of equipment in allergy departments and the 
fact that tests are often performed in respiratory or pediatric 
departments. In addition, scant referral of children with 
respiratory disease from primary health physicians to allergists 
implies that the figure of the allergist is not recognized by the 
general population, pediatricians, or physicians as a specialist 
with competence in the care of asthmatic children. The present 
study reveals for the first time the urgent need to increase use 
of the lung function laboratory by clinical allergists.
To our knowledge, the data we provide are the first to be 
reported on evaluation of allergy and respiratory specialists 
based on expertise in asthma and lung function, which seems 
to be crucial for improving management of asthmatic children. 
Our results show that there is much room for improvement in 
the measurement of lung function and bronchial inflammation 
in children.
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 Bronchodilator test 12 (44.44%) 7 (25.92%) 8 (29.62%) 
 Plethysmography 0 2 (7.40%) 1 (3.70%) 
 Oscillometry 0 0 2 (7.40%)
Bronchial hyperresponsiveness tests Exercise 12 (44.44%) 9 (33.33%) 0 
 Mannitol 11 (40.74%) 1 (3.70%) 0 
 Methacholine 11 (40.74%) 7 (25.92%) 2 (7.40%) 
 Adenosine 1 (3.70%) 0 0 
 Specific bronchial challenge 12 (44.44%) 0 0
Inflammatory tests Exhaled nitric oxide 14 (51.85%) 6 (22.22%) 5 (18.51%) 
 Induced sputum 6 (22.22%) 0 1 (3.70%)
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A 61-year-old woman was referred to our allergy 
department because she had developed erythema of both 
axillae, the inframammary folds, and the cubital and 
popliteal fossae (gluteal and inguinal areas), without systemic 
symptoms, 6 hours after taking, for the first time, etoricoxib 
90 mg to treat osteoarticular pain. She had also taken an 
ibuprofen pill (600 mg) 5 hours before the episode. 
The patient was attended in the emergency room and 
no systemic signs or symptoms were found on physical 
examination. A full blood test with blood count and biochemistry, 
including liver enzymes (aspartate aminotransferase and 
alanine aminotransferase), was performed and showed normal 
results. She was treated with methylprednisolone and achieved 
complete recovery in 5 days, without any residual lesions. 
Etoricoxib and ibuprofen were discontinued. 
The patient had no previous history of drug hypersensitivity 
and while she had tolerated ibuprofen previously, she reported 
never having taken a selective cyclooxygenase 2 (COX-2) 
inhibitor. After this episode, she tolerated paracetamol 1 g. 
She was seen in our allergy department 3 months after the 
initial episode. As we suspected that ibuprofen was the most 
probable cause of the episode, with the patient’s informed 
consent, we first administered a simple-blind oral challenge 
test (SBOCT) with the progressive administration of 
etoricoxib (90 mg). Six hours later, she developed erythema 
of the inframammary folds and inguinal and gluteal areas 
(Figure). She was treated with methylprednisolone, which 
led to complete recovery in 4 days.
Two weeks later, after assessing the risk-benefit profile, 
we performed a closed patch test (Nonwoven Patch Test Strips 
Curatest, Lohmann & Rauscher International) with ibuprofen 
(5%, petrolatum), etoricoxib (8%, DMSO), and celecoxib 
(10%, DMSO) to determinate cross-reactivity. Positive readings 
were obtained for etoricoxib and celecoxib on day 2 and 
day 4. A patch test with DMSO at the same concentration was 
negative. Patch tests with these drugs were also carried out on 
10 healthy control individuals, all of whom had negative results. 
An SBOCT with the progressive administration of a total dose 
of 600 mg of ibuprofen was performed, and was negative.
Etoricoxib is a nonsteroidal anti-inflammatory drug that 
selectively inhibits COX-2. Adverse cutaneous effects with 
DY, Guilbert TW, Hedlin G, Heymann PW, Hong SJ, Hossny EM, 
Huang JL, Jackson DJ, de Jongste JC, Kalayci O, Aït-Khaled N, 
Kling S, Kuna P, Lau S, Ledford DK, Lee SI, Liu AH, Lockey RF, 
Lødrup-Carlsen K, Lötvall J, Morikawa A, Nieto A, Paramesh 
H, Pawankar R, Pohunek P, Pongracic J, Price D, Robertson C, 
Rosario N, Rossenwasser LJ, Sly PD, Stein R, Stick S, Szefler S, 
Taussig LM, Valovirta E, Vichyanond P, Wallace D, Weinberg E, 
Wennergren G, Wildhaber J, Zeiger RS. International consensus 
on (ICON) pediatric asthma. Allergy. 2012 Aug;67(8):976-97.
2. Guilbert TW, Mauger DT, Lemanske RF Jr. Childhood asthma-
predictive phenotype. J Allergy Clin Immunol Pract. 2014 Nov-
Dec;2(6):664-70. 
3. Guilbert T, Moss MH, Lemanske RF: Approach to infants and 
children with asthma. In: Adkinson NF, Brochner BS, Busse 
WW, Holgate ST, Lemanske RF, Simons FER, eds. Middleton’s 
Allergy Principles and Practice. Philadelphia: Mosby; 2009: p. 
1326.
4. Olaguibel Rivera JM, Alvarez Puebla MJ, Aleman EA, Cambra 
K, Uribe San Martin MP, De Esteban Chocarro B. Spirometric 
and exhaled nitric oxide reference values in preschool children 
from the community of Navarra. J Investig Allergol Clin 
Immunol. 2014;24:169-76.
5. Andregnette-Roscigno V, Fernández-Nieto M, Del Potro MG, 
Aguado E, Sastre J. Methacholine is more sensitive than 
mannitol for evaluation of bronchial hyperresponsiveness 
in children with asthma. J Allergy Clin Immunol. 2010 
Oct;126(4):869-71.
6. Korevaar DA, Westerhof GA, Wang J, Cohen JF, Spijker R, Sterk 
PJ, Bel EH, Bossuyt PM. Diagnostic accuracy of minimally 
invasive markers for detection of airway eosinophilia in 
asthma: a systematic review and meta-analysis. Lancet Respir 
Med. 2015 Apr;3(4):290-300.
7. BroquetDucret C, Verga ME, Stoky-Hess A, Verga J, Gehri 
M. Impact of a small-group educational intervention for 4- 
to 12-year-old asthmatic children and their parents on the 
number of healthcare visits and quality of life. Arch Pediatr. 
2013 Nov;20(11):1201-5.
8. Roberts JR, Karr CJ, de Ybarrondo L, McCurdy LE, Freeland KD, 
Hulsey TC, Forman J. Improving pediatrician knowledge about 
environmental triggers of asthma. Clin Pediatr (Phila). 2013 
Jun;52(6):527-33.
9. Janson S, Weiss K. A national survey of asthma knowledge 
and practices among specialists and primary care physicians. J 
Asthma. 2004;41(3):343-8.
10. Moy JN, Grant EN, Turner-Roan K, Li T, Weiss KB. Asthma care 
practices, perceptions, and beliefs of Chicago-area asthma 
specialists. Chicago Asthma Surveillance Initiative Project 
Team. Chest. 1999 Oct;116(4 Suppl 1):154-62S.
128
Practitioner's Corner
J Investig Allergol Clin Immunol 2016; Vol. 26(2): 111-143© 2016 Esmon Publicidad
129
this drug are rare and include leukocytoclastic vasculitis [1], 
fixed drug eruption [2], and Stevens-Johnson syndrome [3]. 
SDRIFE is a type IV hypersensitivity reaction, characterized 
by 5 criteria: exposure to a systemically administered 
drug either following the first or subsequent dose, sharply 
demarcated erythema of the gluteal/perianal and/or inguinal/
perigenital area, involvement of at least 1 other intertriginous/
flexural localization, symmetry of affected areas, and absence 
of systemic symptoms and signs [4].
There has only been 1 published case of SDRIFE due 
to COX-2 inhibitors. It involved a woman who developed 
symmetric pruritic erythematous patches on the abdominal, 
inguinal, and gluteal areas 4 days after the oral administration 
of celecoxib. The patient underwent an SBOCT with celecoxib, 
which yielded a positive result 6 hours after the intake of 
100 mg. Patch tests with celecoxib as is, 50%, and 10% (all 
in petrolatum) were negative. Etoricoxib was not tested [5].
We have reported a case of SDRIFE due to etoricoxib 
confirmed by a positive SBOCT and a positive patch test. 
To our knowledge, this is the first published case of SDRIFE 
caused by etoricoxib. Cross-reactivity with celecoxib was 
demonstrated by a positive patch test. In such cases, avoidance 
of all COX-2 inhibitors should be considered.
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phenotype born from a consanguineous marriage [5]. 
Based on these findings, a diagnosis of MPS-VI was made. 
Following successful decompression surgery for spinal cord 
compression, the patient started walking and urinary-fecal 
incontinence improved following enzyme replacement 
therapy (ERT) for 1 year.
Galsulfase ERT at 1 mg/kg weekly was initiated. 
Pheniramine was administered intravenously at a dose of 
1 mg/kg as premedication for the first 3 infusions. In the 
fourth year of treatment, the patient developed a generalized 
rash over the entire body and on the lips following enzyme 
infusion for 4 hours.
At the time the rash developed, the blood pressure 
measurement was 110/70 mm Hg, and no decrease was detected. 
Infusion was stopped, and 1 mg/kg methylprednisolone and 
1 mg/kg pheniramine were given. After 2 hours, when the rash 
had completely disappeared, infusion was resumed at a lower 
rate. An urticarial rash was observed again after 10 minutes. 
The lips and eyes were also swollen, and cyanosis developed. 
Saturation was measured as 83%, and agitation was observed. 
Blood pressure was measured as 90/55 mm Hg. 
At this point, the infusion was terminated, and oxygen 
and intramuscular adrenaline were administered, followed 
immediately by 2 mg/kg intravenous (IV) methylprednisolone 
and 1 mg/kg pheniramine. The patient improved and was 
discharged without completing enzyme treatment. Neutralizing 
antibody activity detection was 0 dilution factor (DF), and 
anti-rhASB (1 770 000 DF) antibodies were detected in an 
enzyme-linked immunosorbent assay–based antigen–antibody 
assay at 4 weeks after the reaction. A skin test was not 
performed because of the anaphylactic findings, and causality 
was definitive for this reaction.
The drug hypersensitivity reactions observed in the patient 
were considered to be IgE-mediated. Because a standard 
sample desensitization has not been previously reported in the 
literature, we prepared a patient-specific treatment program 
(Table). As premedication, we administered an infusion of 
1 mg/kg IV methylprednisolone and 1 mg/kg IV pheniramine 
12 hours and 2 hours before the enzyme infusion, respectively. 
Three vials were given consecutively after reconstitution 
because the duration of enzyme activity in the formulation 
is 24 hours. 
The aim of this procedure was to use the full enzyme 
preparation. ERT was given over approximately 42 hours, as 
specified in the protocol, for 24 courses of treatment in total. 
Urticaria and anaphylaxis were not observed during this period. 
The skin prick test was applied by standard methods using a 
solution of 1 mg/mL galsulfase in month 6 [6,7]. Because the 
skin prick test was negative, a 1:1000 dilution intradermal 
skin test was performed, yielding an induration and hyperemia 
measuring 30×36 mm and 10×16 mm, respectively. The 
histamine reaction used as a positive control was measured 
as an edematous reaction of 5×5 mm and a hyperemia of 
20×20 mm. Physiological saline was used as a negative control, 
and no reactions were observed.
The protocol was well tolerated. In the desensitization 
protocol, the enzyme infusion time was gradually reduced after 
6 months without adverse effects. Our patient has received 
ERT in 4-hour infusions in the last 2 months. During and 
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Mucopolysaccharidosis type VI (MPS-VI) is a progressive 
lysosomal storage disease characterized by dermatan and 
chondroitin sulfate accumulation in many tissues and 
organs due to N-acetylgalactosamine 4-sulfatase enzyme 
deficiency [1,2]. Disease-specific treatment with galsulfase 
exists. Adverse reactions reported during infusion are fever, 
pruritus, rash, urticaria, headache, hypotension/hypertension, 
abdominal pain, shortness of breath, chills, joint pain, 
hypersensitivity, and anaphylaxis [3]. The rate of serious 
reactions is 2%, and severe infusion-associated reactions have 
been described as infrequent. Clinical trials have not produced 
sufficient data for management considerations[4].
Here we report a case of a recurrent serious infusion-
associated reaction in the fourth year of treatment that 
was successfully managed with a different method of 
desensitization to that described.
A 5-year-old boy with thickened facial features and an 
inability to walk was admitted to our department with urinary 
and fecal incontinence. This boy was born from the mother’s 
seventh pregnancy and was her only surviving child. Three 
prior pregnancies had ended in stillbirths, and of the siblings 
born alive, all boys, 1 died of myelomeningocele at the age 
of 2 months, and the other 2 died at the ages of 5 and 7 years; 
they had had similar symptoms to those of our patient. On 
physical examination, the patient’s height and weight were in 
the third percentile. Thickened facial features, dolichocephaly, 
corneal opacity, upper airway obstruction, pectus carinatum, 
kyphoscoliosis, claw hand, joint range-of-motion limitations, 
bilateral inguinal hernia surgery scars, and a large Mongolian 
spot were present. 
Aortic and mitral valve prolapse, mitral and tricuspid 
valve regurgitation were detected on cardiac evaluation, 
and dysostosis multiplex was evident on radiological 
examination. Arylsulfatase B (ASB) activity was 0 in the 
enzyme analysis (activity of 7.14 in the control assay), 
and a homozygous c.962t>C (p.l321p) mutation was 
identified in the ASB gene. The same mutation was first 
described in homozygosis in a patient with an intermediate 
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after this protocol, no adverse effects were seen in relation to 
corticosteroid use. 
To continue ERT in MPS-VI patients receiving rhASB, 
corticosteroid use may be considered 12 hours and 1 hour 
before the infusion when an infusion reaction develops 
despite using antipyretics and antihistamines [3]. In the 
literature, there is no standard desensitization program, 
and only a small number of cases involving treatment of 
infusion-associated reactions have been reported [8,9]. 
Complications and/or adverse effects from the long-term 
use of corticosteroids administered for desensitization 
were not detected in our patient. Considering the potential 
benefits, the objective in this case was to continue ERT, and 
indeed, we identified multisystemic positive effects with this 
therapy in our patient. Our premedication and desensitization 
protocol has been beneficial in this case, but more reports 
of desensitization management in a larger number of cases 
are needed to develop a standardized protocol for infusion-
associated reactions.
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Cetuximab (Erbitux, Merck KGaA) is an IgG1 chimeric 
monoclonal antibody that binds specifically to the extracellular 
domain of the human epidermal growth factor receptor (EGFR). 
It is approved for the treatment of RAS wild-type metastatic 
colorectal cancer as well as head and neck cancer. Severe 
reactions tend to occur during the first administration [1]. In 
2008, severe anaphylactic reactions after the first infusion of 
cetuximab were reported for the first time, and the authors 
demonstrated that pre-existing specific IgE (sIgE) antibodies 
to galactose-alpha-1,3-galactose (alpha-gal) were responsible 
for the reactions [2]. Alpha-gal is present on the Fab portion of 
the cetuximab heavy chain. Very few cases of desensitization 
to cetuximab have been described since these first reports 
of severe reactions [3-5]. Moreover, in recent years, severe 
hypersensitivity reactions to red meat with a delay of several 
hours have been reported in patients with IgE to alpha-gal [6]. 
Here, we present the case of a 50-year-old man without a 
previous history of atopy or drug allergy who was diagnosed 
with pyriform sinus squamous cell cancer in 2014. The 
cancer was treated by surgery followed by chemotherapy and 
radiation therapy. The disease progressed, however, and a year 
later the patient was diagnosed with lung metastases. 
In April 2015, the patient experienced dizziness, severe 
hypotension, visual disturbances, and chills 15 minutes after 
starting to receive the first dose of intravenous cetuximab. 
The infusion rate was 5 mg of cetuximab per minute, as 
recommended by the manufacturer. No urticarial reactions 
were noted. Prior to administration, the patient had been 
prophylactically treated with intravenous ondansetron, 
dexamethasone, ranitidine and dexchlorpheniramine. The 
infusion of cetuximab was stopped, and the patient showed 
gradual improvement with the administration of corticosteroids 
and fluid therapy. Epinephrine was not administered at the 
discretion of the oncology infusion service. Serum tryptase 
was not measured during the reaction. The patient did not 
receive the previously programmed first dose of paclitaxel 
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as associated therapy for his cancer, although a week later 
he started to receive a weekly therapeutic dose of paclitaxel, 
which he tolerated well. The patient was referred to our drug 
allergy unit for evaluation following this reaction. 
Skin prick and intradermal tests were performed with 
cetuximab. The skin prick test with undiluted cetuximab 
(5 mg/mL) was negative, but the intradermal test (1:1000 
dilution) was clearly positive. The skin tests were performed 
in accordance with previously published recommendations [7]. 
Although skin tests with cetuximab have not been yet 
validated, there are several reports of the absence of nonirritant 
reactions with even higher concentrations than the one we 
used [5-8]. We measured baseline serum tryptase and total 
IgE and specific IgE levels to alpha-gal using the ImmunoCAP 
system. The serum tryptase level was normal (4.2 µg/L). 
Total IgE was elevated (112 IU/mLl) and specific IgE against 
alpha-gal was positive (1.14 kU/L). Thus, the patient was 
diagnosed with IgE-mediated hypersensitivity to cetuximab 
demonstrated by in vivo and in vitro tests. We suggested to his 
oncologist that cetuximab administration could be achieved 
via a desensitization protocol, as demonstrated for other 
antineoplasic agents. The oncologist approved this option. 
Cetuximab desensitization was pursued after specific 
informed consent was obtained from the patient. We used a 
10-step rapid desensitization protocol as previously described 
by Madrigal-Burgaleta et al [7] (Table). This protocol is a 
modified, shorter version of the standardized Brigham and 
Women´s Hospital protocol [9] and lasts approximately 255 
minutes. It also complies with the safety measures defined 
for hazardous drug handling by nursing staff. We use this 
protocol to achieve desensitization to different drugs at our 
drug allergy unit. All desensitizations are performed at this 
unit, which has a dedicated area containing 10 beds for patients 
with drug allergy problems. The area is located very near to 
the hospital’s intensive care unit. The patient was provided 
with one-to-one nurse to patient care, with surveillance by 
trained expert personnel, as recommended [1,5,7,9]. We 
administered a total cumulative therapeutic dose of 440 mg of 
cetuximab (250 mg/m2). Three different solutions of cetuximab 
(A, B, and C) diluted in 250 mL of sodium chloride were used. 
Premedication with oral acetylsalicylic acid (300 mg) and 
montelukast (10 mg) daily was administered on the 2 days prior 
to desensitization as well as on the day of the procedure. Just 
before starting the desensitization procedure, we administered 
intravenous dexchlorpheniramine (5 mg) and dexamethasone 
(12 mg) following the manufacturer's instructions, in addition 
to intravenous ondansetron (8 mg) and ranitidine (50 mg). 
Throughout the desensitization, the patient’s vital signs 
remained stable, and no symptoms were observed. 
We repeated this protocol weekly for 9 consecutive weeks 
with the same cumulative dose of cetuximab, recommended 
by the oncologist. On all occasions, the patient’s vital signs 
remained stable, and no symptoms were noted. After these 9 
weeks we retested specific IgE against alpha-gal, and the result 
was negative (0.15 kU/L).
In 2009, Jerath et al [3] described the use of a successful 
cetuximab desensitization regimen in a patient with an IgE-
mediated hypersensitivity reaction who required continuation 
of treatment, similarly to our patient. They used 5 different 
solutions of cetuximab and 20 steps, and described pre-
existing detectable anti-cetuximab IgE antibodies (1.06 kU/L). 
However, they did not perform skin tests with cetuximab. In 
the same year, Saif et al [4] attempted empirical desensitization 
in 2 patients who had had acute reactions to panitumumab, a 
humanized monoclonal antibody against EGFR. These patients 
were successfully switched to cetuximab therapy using this 
empirical desensitization protocol. However, it is unclear 
whether either of the patients described had hypersensitivity 
Table. 10-Step Cetuximab Desensitization Protocol Modified From Madrigal-Burgaleta et al [7]a   
Total Dose 440 mg  Solution   Total Dose 
   Concentration  in Each Solution, mg 
Solution A 250 mL  0.03520 mg/mL  8.8000 
Solution B 250 mL  0.35200 mg/mL  88.000 
Solution C 250 mL  1.48896 mg/mL  372.24 
Step Solution Rate, mL/h Administered Time, min Administered Cumulative Dose 
   Volume, mL  Dose, mg Infused, mg
1 A 88 22 15 0.0 0.0 
2 A 100 25 15 0.88000 0.88000 
3 A 200 50 15 1.76000 2.64000 
4 A 400 100 15 3.52000 6.16000 
5 B 88 22 15 0.0 6.16000 
6 B 100 25 15 8.80000 14.96000 
7 B 200 50 15 17.6000 32.56000 
8 B 400 100 15 35.2000 67.76000 
9 C 88 22 15 0.0 67.76000 
10 C 125 250 120 372.24000 440.00000
aThe solutions were prepared by the pharmacy department’s cytotoxic unit. Hong et al [5] argued that they did not dilute their solutions because 
cetuximab is distributed at a fixed concentration in a proprietary buffer solution. However, the pharmacy department at our hospital did not 
find any warning from the manufacturers or any other data indicating that diluted or very diluted cetuximab in a saline solution could affect its 
stability or properties.
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to cetuximab, because neither of them had received cetuximab 
previously or been evaluated for the presence of preformed 
anti-cetuximab IgE.
In a later study, Hong et al [5] reported a successfully 
managed hypersensitivity reaction using a 1-solution, 5-step 
desensitization protocol. Skin tests to cetuximab were positive 
on intradermal testing using a 1:10 dilution. The protocol was 
carried out 7 times and the patient showed no reactions on any 
of the occasions. The authors did not measure specific IgE 
to cetuximab. A strong correlation between the occurrence 
of hypersensitivity reactions to cetuximab and the presence 
of anti-cetuximab IgE in the sera of patients before an initial 
injection of cetuximab has been demonstrated, and fatal 
reactions have even been reported [10].
In conclusion, we have described a successful, safe weekly 
cetuximab desensitization protocol in a patient with an IgE-
mediated hypersensitivity systemic reaction to cetuximab, 
demonstrated by both a positive skin test to cetuximab and 
specific IgE to alpha-gal. Early signs of anaphylaxis, such as 
cutaneous symptoms, may not have been present on the day 
of the reaction because the patient was premedicated before 
receiving cetuximab. Desensitization protocols such as the 
one described here permit patients to continue safely with 
first-choice therapies, leading to improved prognosis. The 
protocols should be implemented with the involvement of 
a multidisciplinary team and drug desensitization experts in 
appropriate facilities. To our knowledge, there have been no 
previous reports of successful desensitization to cetuximab 
in patients with both a positive skin test and specific IgE. Of 
particular note in our case is the negative result for specific 
IgE against alpha-gal after desensitization. Others patients 
with demonstrated hypersensitivity reactions to cetuximab 
could benefit from using such a protocol.
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Erythritol is a natural sugar alcohol produced by glucose 
fermentation. It is contained in fruit, mushrooms, and 
fermented foods such as wine, soy sauce, and bean paste [1]. 
More than 90% of ingested erythritol is not metabolized and is 
excreted unchanged in the urine. Thus, erythritol is considered 
to have very few calories (0.24 kcal/g). In Japan, erythritol has 
been widely used as a sweetener and consumed in low-calorie 
foods and toothpastes since 1990. Here, we report a case of 
immediate-type allergy to erythritol, as examined in vitro by 
the basophil histamine release test (HRT) and the expression 
of CD203c on basophils, along with an in vivo challenge test 
with erythritol.
An 18-year-old woman with a history of atopic dermatitis 
in childhood experienced anaphylaxis after eating desserts on 
3 occasions. During the first episode, she experienced systemic 
urticaria after eating a piece of chocolate cake. During the 
second episode, after eating jelly containing 11 g of erythritol, 
she developed systemic urticaria with abdominal pain, and 
then lost consciousness. During the third episode, this time 
after eating ice cream, she developed systemic urticaria and 
had respiratory difficulties. A skin prick test with erythritol 
dissolved in distilled water showed no reactions, even at a 
concentration of 200 mg/mL. We then performed an oral 
challenge test at our hospital. No symptoms were observed 
with 0.11 g and then 0.37 g of erythritol powder, equivalent to 
1% and 3.3% of the erythritol contained in the jelly ingested 
in the second episode. However, 13 minutes after taking 
1.1 g of erythritol (10% of the amount ingested in the second 
episode), wheals, eyelid edema, oral discomfort, and cough 
were observed. These symptoms disappeared shortly after 
treatment with an antihistamine and a corticosteroid. Neither 
wheezing nor hypotension was induced in this challenge test. 
As in vitro tests, we performed an HRT and a basophil 
activation test (BAT). The HRT with basophils from the patient 
and 2 healthy adult volunteers did not show any release of 
histamine by erythritol at concentrations from 0.1 mg/mL to 
10 mg/mL (data not shown). By contrast, the BAT, performed 
with the Allergenicity Kit (Immunotech, a Beckman Coulter 
Company) showed small, but apparent, surface expression 
of CD203c on basophils of the patient induced by erythritol 
in a concentration-dependent manner (Figure). Sucrose, 
another sugar alcohol, did not induce any changes in CD203c 
expression on the patient’s basophils, and basophils obtained 
from the 2 volunteers showed no reactions to either erythritol 
or sucrose. Based on these observations, we diagnosed the 
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Figure. Basophil activation test (BAT) with erythritol and sucrose. 
Whole blood of patient (Pt) and 2 healthy adult volunteers (H1, H2) 
was stimulated with erythritol (E0.1, 0.1 mg/mL; E1, 1 mg/mL; E10, 
10 mg/mL), sucrose (S0.1, 0.28 mg/mL; S1, 2.8 mg/mL; S10, 28 mg/mL), 
negative control (NC), or positive control (PC, anti-IgE antibody supplied 
in the Allergenicity Kit); the expression of CD203c on basophils was then 
analyzed by flow cytometry.
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patient’s reaction as an erythritol-induced immediate-type 
allergy. We instructed her not to eat food containing erythritol, 
and to date, she has not experienced any anaphylactic episodes.
As far as our extensive review of the literature revealed, 
only 7 cases of erythritol allergy, including our case, have 
been reported [1-5]. The mean (SD) age of the 7 patients is 
20.6 (15.4) years old, and 4 of them were female. Five patients 
undertook oral challenge tests, and they all had positive 
reactions. Intradermal skin tests with erythritol were performed 
in 3 cases and they were all positive. However, only 4 (57%) of 
the 7 patients showed a positive result against erythritol in the 
skin prick tests, suggesting that a negative skin prick test result 
by itself is insufficient to rule out erythritol-induced allergy.
The HRT was negative in all 3 patients described in the 
literature, whereas the BAT was positive in all 4 cases in 
which it was used. Our case is the first report of the use of 
both the BAT and HRT against erythritol using basophils from 
the same patient. In the HRT, peripheral blood basophils are 
isolated from whole blood and incubated with the substances 
to be tested; the amount of histamine released from the 
basophils is measured as an index of activation. The BAT, 
by contrast, analyzes, via flow cytometry, cell markers (eg, 
CD203c) expressed on the surface of activated basophils, 
using whole blood and stimuli. Thus, the performance of the 
BAT is somewhat more physiological than that of the HRT in 
that basophils are stimulated in whole blood, rather than by 
themselves. Generally, small molecules of less than 1000 Da 
have no antigenicity by themselves in buffer solution. Thus, 
they must bind to carrier macromolecules such as hapten [6] to 
evoke an immediate-type allergic reaction. Since the molecular 
weight of erythritol is small (approximately 122 Da), erythritol 
alone should not have antigenicity. Previous reports have 
suggested that erythritol molecules might gain antigenicity 
by binding to plasma proteins [1,3]. However, pretreatment 
of erythritol with serum of the patient did not significantly 
increase histamine release in the HRT (data not shown), 
implying that mechanisms other than those underlying the 
“hapten theory” for erythritol might have been involved 
in our patient. Alternatively, the enhanced expression of 
CD203c by erythritol may not be related to the degranulation 
of basophils [7].
In conclusion, we have reported a case of erythritol-
induced immediate-type allergy with a negative HRT result 
and a positive BAT result. To diagnose an allergic reaction with 
small molecules like erythritol, BAT is worth trying regardless 
of the result of the HRT.
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Clinical experience with the measurement of fractional 
exhaled nitric oxide (FeNO) suggests that this technique 
has a promising role in the identification of eosinophilic 
airway inflammation in population-based settings, including 
epidemiological studies and asthma screening. This 
noninvasive marker could serve as a potentially useful tool 
for the detection of early stages of asthma in children on the 
assumption that a cutoff point of 35 ppb would indicate airway 
inflammation, while levels of below 20 ppb would make such 
a diagnosis unlikely [1]. However, more evidence is needed 
regarding physiological values and determinants of FeNO in 
healthy children [2,3]. 
Numerous factors have been found to affect FeNO levels 
in healthy children, including age, sex, height, weight, 
diet, atopy, genetics and smoking; of these age is the most 
important factor [1]. The evidence for other determinants of 
FeNO in healthy children is less conclusive [4]. In the area 
of anthropometric variables, chest size could be taken into 
account as a potential correlate of FeNO levels. Moreover, it 
cannot be excluded that FeNO levels relate to lung function 
in healthy children. 
The aim of the study was to assess the association between 
FeNO levels and chest size and lung function in healthy 
children aged 6 to 9 years, which is an age group frequently 
chosen for respiratory health surveys. In order to achieve this 
aim, we analyzed the correlation between FeNO levels and 
chest circumferences and spirometric variables. 
The study was performed in Silesian Voivodeship, 
Poland. The targeted participants were 525 children from 7 
primary schools randomly selected in the towns of Bytom 
and Chorzów; the parents of 385 of these children agreed to 
their participation in the project. Based on the answers to the 
ISAAC questionnaire, 129 children without a diagnosis of 
asthma, spastic bronchitis, hay fever, atopic eczema or other 
allergic diseases, chest wheezing out of the cold, and recent 
dyspnea attacks (in previous 12 months) were included in the 
study. The measurements included height (cm), body mass 
(kg), and chest circumferences (cm) during inhalation and 
exhalation. Forced vital capacity (FVC), forced expiratory 
volume in the first second (FEV1), FEV1/FVC ratio, and indices 
of forced expiratory flow (FEF) at different percentages of vital 
capacity (FEF25, FEF50, FEF75) were obtained according to the 
recommendations of the American Thoracic Society and the 
European Respiratory Society using an EasyOne spirometer 
(NDD Medical Technologies); the results were expressed in 
absolute values and percentage of predicted values [5]. FeNO 
was measured with the children in a sitting position using the 
NIOX MINO device (Aerocrine). The test was composed of 
a maximum of 5 attempts until 1 acceptable measurement 
was obtained. 
The statistical significance of differences in quantitative 
variables was evaluated using the nonparametric Wilcoxon 
test. Associations between FeNO levels and spirometric 
variables, chest size measurements, and demographic variables 
were examined using Spearman correlation analysis and 
verified by multivariate linear regression analysis with FeNO 
as the dependent variable. Separate models were analyzed for 
each candidate explanatory variable (FVC, FEV1, FEV1/FVC, 
and chest circumferences), controlled for sex, age, and height. 
Statistical significance was set at a P level of less than .05. The 
study protocol was approved by the ethics committee at the 
Medical University of Silesia (decision number, KNW/0022/
KB1/37/I/14). 
The study group was composed of  84 children (girls, 38.1%) 
aged 6 to 9 years who provided acceptable measurements. 
FeNO levels were above 20 ppb in almost all the children 
(90.5%), between 20 and 35 ppb in 8.3%, and above 35 ppb 
in 1.2% (1 child). Mean (SD) FVC was 104.1% (13.3%) of 
predicted, mean FEV1 was 96.8% (10.2%) of predicted, mean 
FEV1/FVC was 86.8% (5.9%) of predicted, and mean chest 
circumference was 61.1 (5.4) cm on exhalation and 65.9 
(5.3) cm on inhalation (mean relative difference, 7% [1%]). 
Mean FeNO was 12.3 (7.9) ppb and individual values did 
Table. Association Between Fractional Exhaled Nitric Oxide (FeNO) and Chest Circumferences: Results of Multivariate Regression Analysis
Model                P values for regression coefficients (type III sum of squares) 
FeNO = Sex Age Height Chest  Chest Relative difference 
sex+age+height+:    circumference circumference of chest 
    (exhalation) (inhalation) circumferences
+ chest circumference (exhalation) .3 .7 .02 .02 - -
+ chest circumference (inhalation) .2 .8 .03 - .07 -
+ relative difference between  
chest circumferences .6 .5 0.1 - - .02
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not correlate with sex, age, weight, or spirometric variables 
expressed as percentage of predicted; they were, however, 
related to height (r=0.25, P=.02) and difference between chest 
circumferences on inhalation and exhalation (r=0.24, P=.02). 
In a set of separate multivariate regression models, FeNO 
appeared to be associated with chest circumferences and height 
(Table). On controlling for sex, age, and height, FeNO was not 
significantly associated with spirometric variables. Children 
with a FeNO above 20 ppb had similar lung function (% of 
predicted) compared with the remaining individuals (FVC, 
104.1% vs 105.1%; FEV1, 96.8% vs 96.9%; FEF25, 90.9% 
vs 94.4%; FEF50, 103.4% and 103.7%; and FEF75, 91.1% 
vs 105.0%). This last difference was statistically significant 
(P=.03).
Our findings showed the role of height and chest size 
measurements among correlates of FeNO in healthy children. 
We did not observe the effect of age reported for children 
younger than 12 years of age [1]. The absence of this effect 
in our study could be explained by the narrow age span of the 
children examined.
In asthmatic children the correlation between FeNO 
levels and spirometric outcomes is weak but interestingly 
FeNO levels are associated with bronchial responsiveness in 
children with and without respiratory symptoms [6]. Our study 
of children without known respiratory disorders showed that 
FeNO did not correlate with spirometric variables in this group 
of children, although FEF75 levels were lower in children with 
FeNO above 20 ppb than in children with FeNO below 20 ppb. 
This finding may suggest potential involvement of a “small 
airway” component and requires further exploration. Similarly, 
in a group of 60 healthy Spanish children, no correlations 
were observed between FeNO and FVC, FEV1, FEV1/FVC 
ratio, or FEF50 [7].
In our study, chest size was expressed by 2 measurements: 
circumference on inhalation and circumference on exhalation. 
Each of these measurements, as well as the relative difference 
between them, appeared to correlate with FeNO after 
adjustment for sex, age, and height. Such a relationship is in 
line with the concept that FeNO levels are associated with 
airway size. However, the finding is not supported by the effect 
of vital capacity on FeNO.
Our study has some limitations. First of all, it involved a 
small group of individuals. Secondly, the protocol included 
indirect markers of airway size, namely chest circumferences 
and lung capacities and volumes. Nevertheless, based on our 
findings we suggest that the effect of airway size on FeNO 
cannot be ignored. Studies addressing that issue should 
contribute to the discussion on physiological values of FeNO 
with a potential benefit in the field of respiratory epidemiology.
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Difficult-to-control asthma is defined as asthma in which 
associated comorbidities and/or triggers are not controlled or 
in which other entities that could cause asthma have not been 
eliminated. These factors hinder the daily control of asthma 
and complicate the prevention of exacerbations [1].
Gastroesophageal reflux disease (GERD) can occur in 
association with uncontrolled severe asthma [2], but we now 
know that many patients diagnosed with refractory GERD 
in the late 20th century actually had eosinophilic esophagitis 
(EoE) [3,4].
A 29-year-old woman with a previous history of pollen-
induced allergic rhinoconjunctivitis and asthma that clearly 
improved after pollen immunotherapy administered over 3 
years had been asymptomatic for the previous year except for 
exercise-induced asthma in the springtime. She came to our 
clinic complaining of nocturnal breathlessness, dry cough, and 
dyspnea on minimal exertion for the past 6 months, despite 
treatment with salmeterol and fluticasone (50/500 mcg) 
and montelukast. Wheezing was observed on physical 
examination. Spirometry and chest radiography were normal. 
Skin prick tests were positive to pollens and negative to mites, 
fungi, and epithelia. Total IgE was 800 kU/L and specific 
IgE (kU/L) showed high titers to lolium (>100 kU/L), olive 
(>100 kU/L), and cypress (6 kU/L) pollens. The eosinophil 
cationic protein showed a figure of 18 mcg/L. 
The dose of inhaled corticosteroids was increased, but 2 
weeks later the patient required urgent treatment due to an 
asthma exacerbation. She was discharged from the emergency 
room within 24 hours, and continued with the same treatment 
plus a cycle of descending doses of oral corticosteroids.
During the following 4 months she experienced 5 asthma 
exacerbations, with persistent coughing and an episode of 
choking, despite treatment with deflazacort. Moreover, she 
complained of vomiting and epigastric pain over the previous 
week and had only been able to tolerate liquids in the last 2 to 
3 days. On physical examination she showed tachypnea when 
speaking and scattered wheezing was detected on auscultation. 
The spirometry showed bronchial obstruction (spirometry 1, 
Table) with a positive bronchodilator test (14% increase in 
forced expiratory volume in the first second). A chest x-ray and 
a computed tomography thorax scan showed a rounded image 
in the upper lobe of the left lung. The patient was admitted 
and diagnosed with a lung abscess. 
An upper digestive endoscopy was requested but it 
could not be performed until 3 weeks later due to the 
intense esophageal edema. When the endoscopy was finally 
performed, a “ringed esophagus” was found; 5 biopsies 
of the esophagus were obtained and over 50 eosinophils 
per high power field (eos/hpf) were detected in all the 
samples. Biopsies of the stomach and duodenum showed 
no eos/hpf. The patient was diagnosed with EoE. After 2 
months of therapy with omeprazole (80 mg/d), a new upper 
endoscopy showed over 25 eos/hpf in all the esophageal 
biopsy samples [3].
The patient improved after treatment with amoxicillin-
clavulanic acid, bronchodilators, and oral corticosteroids. 
At discharge, she continued with her asthma treatment. The 
patient chose to follow symptomatic treatment for EoE (oral 
fluticasone 440 ugs/12 h) [5] rather than an elimination 
diet [6,7]. 
Six months later, the patient had only mild dysphagia 
and no symptoms of asthma (spirometry 2, Table) despite 
a progressive reduction in asthma treatment, which was 
Table. Spirometry Results for Patient Over the Course of Evaluation and Treatmenta
Spirometry FEV1, L FVC, L FEV1/FVC FEF25-75, L/s PEF, L/s
1 2.05 (68%) 3.21 (93%) 63% 1.31 (34%) 3.30 (48%)
2 3.07 (103%) 3.22 (94%) 95% 3.22 (94%) 4.88 (71%)
3 2.40 (82%) 3.23 (95%) 74% 1.94 (50%) 4.16 (61%)
4 3.08 (105%) 3.28 (96%) 93% 4.68 (122%) 6.67 (99%)
5 2.96 (102%) 3.29 (98%) 90% 4.70 (124%) 7.8 (117%)
Abbreviations: FEV1, forced expiratory volume in the first second; FEV25-75, forced expiratory flow at 25% to 75% of vital capacity; FVC, 
forced vital capacity; PEF, peak expiratory flow.
aResults shown as absolute values and percentage of predicted.
Practitioner's Corner
J Investig Allergol Clin Immunol 2016; Vol. 26(2): 111-143 © 2016 Esmon Publicidad
eventually stopped; she only received oral fluticasone 
440 µg/12 h for EoE. 
One year later she had no symptoms of esophageal 
dysfunction. A new esophagoscopy with biopsy was performed; 
the EoE had subsided (2 eos/hpf) and oral fluticasone was 
removed. After 25 days, the patient experienced a further 
exacerbation and came to the emergency room complaining of 
dysphagia and dyspnea of 1 week’s duration. The spirometry 
data at that time is shown in the Table (spirometry 3). Asthma 
therapy (salmeterol and fluticasone 50/250 µg) was restarted. 
A new esophagoscopy confirmed reactivation of the EoE (>30 
eos/hpf in the 3 sections of the esophagus). The patient decided 
to start treatment with an elimination diet. An allergy study 
including skin tests and specific IgE to milk, cereal, eggs, 
legumes, fish/seafood, and nuts was negative.
One month after starting the six food elimination diet, 
the patient was asymptomatic and the spirometry was normal 
(spirometry 4, Table). No eos/hpf were found in any segment 
of the esophagus, although the “ringed oesophagus” persisted. 
The patient experienced asthma exacerbations, with dry cough, 
dyspnea, and wheezing, a month after introducing milk and 
again when she started eating legumes; spirometry, however, 
was normal. A new esophagoscopy confirmed reactivation of 
the EoE (>50 eos/hpf). There were no histological or clinical 
signs of reactivation upon introducing the other foods into her 
diet. The patient is currently following a milk- and legume-
free diet and has no digestive symptoms. Further endoscopies 
have shown no eosinophils and she has only needed rescue 
salbutamol for isolated asthma attacks in the spring of the last 
2 years (spirometry 5, Table) and for mild symptoms triggered 
by respiratory infections.
We have described a case of a patient with uncontrolled 
asthma in which respiratory and esophageal symptoms followed 
a parallel course. A lung abscess, probably a consequence of 
microaspirations due to the intense esophageal edema [1], led 
to the admission of our patient; following this, her asthma 
got worse whenever her digestive symptoms appeared. On 
3 occasions, (upon removing oral topical corticosteroids and 
after introducing legumes and cow's milk into her diet), she 
also experienced exacerbation of her asthma. The patient’s EoE 
has been in remission for the last 2 years, during which time 
she has been following an elimination diet; she has had only 
occasional symptoms of asthma. These observations suggest 
that the EoE in this patient acted as a comorbidity interfering 
with asthma control.
The approach to severe uncontrolled asthma requires 
the detection and control of comorbid conditions to control 
the disease, although it is sometimes difficult to know to 
what extent the comorbidity influences the development and 
maintenance of difficult-to-control asthma [8-10]. We suggest 
investigating symptoms of esophageal dysfunction in such 
cases, particularly in atopic patients, in order to rule out not 
only GERD but also EoE.
The clinical course observed in our patient and the results 
of the studies performed suggest that this patient’s difficult-to-
control asthma was triggered by a new comorbid disease not 
described so far: eosinophilic esophagitis due to cow's milk 
and legumes. More studies, however, are needed to evaluate 
this association.
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IgE-mediated sensitization to aeroallergens, and to dust 
mite allergens in particular, is an important risk factor for 
asthma [1]. Some studies have suggested that exposure to 
dust mite allergens could contribute to the severe form of this 
disease, showing a positive correlation between dust mite 
sensitivity and asthma severity [2-3]. Patients with severe 
asthma are particularly difficult to treat [4]. Thus, accurate 
identification of specific sensitization is very important for 
the successful control of severe asthma through appropriate 
treatments in atopic patients [3]. Skin tests and specific IgE 
quantification with traditional assays are typically used by 
clinicians to identify the cause of allergies, but these tests 
do not provide an absolute predictive value [5]. Molecular 
diagnosis has recently been introduced into the field of 
allergology. The ImmunoCAP ISAC test uses more than 
100 purified natural and recombinant allergen components 
spotted onto a microarray plate, allowing the quantification 
of specific IgE against a large number of allergens with only 
30 µL of serum sample. Moreover, this test has been shown 
to discriminate between genuine allergy and sensitization, 
and to identify cross-reactivity to proteins with similar 
protein structures [5-6]. It has been demonstrated both with 
challenge and epidemiological studies that mite sensitization 
is a marker of allergic asthma [7-9]. The main dust mite 
allergens are proteins from Dermatophagoides pteronyssinus 
(Der p) (Der p 1, Der p 2 and Der p 10) and Dermatophagoides 
farina (Der f) (Der f 1 and Der f 2), and high cross-reactivity 
between different dermatophagoides allergens from groups 
1 and 2 has been demonstrated [6].The ImmunoCAP ISAC 
technique could therefore be of interest in this context. To 
confirm that dust mite sensitization is a marker of asthma 
severity and to determine whether the ImmunoCAP ISAC 
test allows discrimination between patients with intermittent, 
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mild to moderate persistent, and severe persistent asthma 
according to sensitization profiles, we compared aeroallergen 
sensitization profiles of patients with atopic asthma by using 
the skin prick test and the ISAC technique. This study was 
performed in 2011 drawing from the data of 126 patients aged 
18 to 74 years diagnosed with atopic asthma in the pneumology 
department of the University Hospital of Strasbourg in France. 
The following clinical data were collected from the patients’ 
medical records: forced expiratory volume in the first second 
(FEV1), rhinitis and conjunctivitis diagnosis, treatments, and 
skin prick tests results. Patients treated with omalizumab and 
patients with nonatopic asthma were excluded. The patients 
included in this study were divided into 3 groups based on their 
asthma severity (intermittent, mild to moderate persistent, and 
severe persistent) according to the former Global Initiative 
for Asthma classification [10]. Serum samples kept at -20°C 
were defrosted in order to perform the ImmunoCAP ISAC test. 
Skin prick tests were performed using commercial extracts of 
a panel of aeroallergens including dust mite, cat, and pollens 
(ash, grass, and birch pollen) (Stallergenes). Skin reactions 
were assessed after 20 minutes. Results were considered 
142
positive when the mean wheal diameter was at least 3 mm 
greater than the negative control. Serum specific IgE was 
quantified for all patients using the commercial allergen 
microarray ImmunoCAP ISAC version CRD103 following the 
manufacturer’s instructions (Thermo Fisher Scientific, Phadia 
SAS). Values superior to 0.3 ISAC Standardized Units (ISU) 
were considered positive according to the manufacturer’s 
recommendation. Percentages from the 3 asthma severity 
groups were compared using the χ2 test, while means were 
compared using 1-way analysis of variance. All analyses were 
performed using SAS version 9.3 (SAS Institute). Differences 
were considered statistically significant when the P value was 
less than .05. Of the 126 individuals enrolled in our study 39 
had intermittent asthma and 87 had persistent asthma (mild to 
moderate in 42 cases and severe in 45). The characteristics of 
the patients and results are presented in the Table. The patients’ 
mean age was significantly higher in the severe asthma group, 
and rhinitis and conjunctivitis were significantly less frequent 
in these patients. Skin prick test results showed no significant 
differences between the 3 groups of asthmatics for sensitization 
to dust mite, cat, grass, and ash allergens. However, birch 
Table. Demographic and Clinical Characteristics of the Patients and Results of the Studya
Characteristics  Groups According to Asthma Severity   Total P Valueb 
  Intermittent Mild to Moderate Severe Population 
  (n=39) (n=42) (n=45) (n=126)
Mean age, y 34.7 37.5 47.9 40.4 <.0001 
 Range 18-66 18-68 21-74 18-74 
 SD 12.8 12.6 15.7 14.9 
Sex, No. (%)          
 Men 18 (46.2) 14 (33.3) 20 (44.4) 52 (41.3) .436 
 Women  21 (53.8) 28 (66.7) 25 (56.6) 74 (58.7) 
FEV1, % (range) 98.8 (75-128) 82.85 (57-111) 70.69 (28-124) 
Missing values, No. 27 22 19  
Rhinitis, No. (%) 35 (89.7) 36 (85.7) 26 (57.8) 97 (77.0) .0006
Conjunctivitis, No. (%) 33 (84.6) 24 (57.1) 8 (17.8) 65 (51.6) <.0001
Treatment, No. (%) 
 Inhaled corticosteroid 10 (25.6) 42 (100.0) 45 (100.0) 97 (77.0) 
 β2-agonist (long-acting) 18 (46.2) 30 (71.4) 42 (93.3) 90 (71.4)
Results      
 Skin prick test sensitization, No. (%)      
 Dust mite allergen 19 (48.7) 23 (54.8) 29 (65.9) 71 (56.8) .273 
 Birch pollen 21 (53.9) 17 (40.5) 7 (15.9) 45 (36.0) .001
ImmunoCAP ISAC, No. (%)  
     Dust mite allergen 17 (43.6) 17 (40.5) 29 (64.4) 63 (50.0) .052 
     Birch pollen 25 (64.1) 17 (40.5) 13 (28.9) 55 (43.7) .005
Sensitization to Der p 2, No. (%) 
(ImmunoCAP ISAC) 14 (35.9) 14 (33.3) 26 (57.8) 54 (42.9) .040
Sensitization to Der f 2, No. (%) 
(ImmunoCAP ISAC) 14 (35.9) 14 (33.3) 28 (62.2) 54 (44.4) .011
Abbreviation: FEV1, forced expiratory volume in the first second. 
aPercentages of positive skin prick test and specific IgE results by ISAC microarray were calculated for birch pollen (Bet v 1 and Bet v 4) and 
dust mite (Der p 1, Der p 2, Der f 1, Der f 2, Der p 10, and acarieneur2). 
bP values, calculated using the χ2 test, show differences of proportions between the 3 groups (intermittent asthma, mild to moderate asthma, and 
severe asthma).
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pollen sensitization was significantly less common in patients 
with severe persistent asthma (15.9%) than in those with 
intermittent asthma (53.9%) or mild to moderate persistent 
asthma (40.5%). The ImmunoCAP ISAC test showed similar 
results with a significant difference between the 3 groups for 
birch pollen sensitization only. However, in contrast to the 
skin prick tests results, the difference across the 3 groups 
was close to statistical significance for dust mite allergens 
(P=.052). Furthermore, when the intermittent and mild to 
moderate persistent asthma groups were considered together, 
the proportion of dust mite sensitivity in this merged group 
was significantly lower than in the severe asthma group (42.0% 
vs 64.4%, P=.01). This result shows that patients with severe 
persistent asthma were more sensitized to dust mite than other 
patients. When dust mite allergens (Der p 1, Der p 2, Der f 1, 
Der f 2, Der p 10) were analyzed separately, the ISAC results 
demonstrated significant differences between the 3 groups 
for Der p 2 (P=.040) and Der f 2 (P=.011), with more frequent 
sensitization to both allergens observed in patients with severe 
asthma. Some studies have suggested a positive correlation 
between dust mite sensitization and asthma severity [2-3]. 
However, our skin prick test results did not demonstrate a 
significant difference in dust mite sensitization across the 
3 groups of patients with asthma. Interestingly, the results 
obtained with the ImmunoCAP ISAC method showed that 
compared with patients with milder stages of asthma, those 
with severe persistent asthma were more frequently sensitized 
to dust mite allergens, especially to Der p 2 and Der f 2. Thus 
the ImmunoCAP ISAC test allows significant discrimination 
between patients with severe asthma and others according 
to dust mite sensitization. Both the skin prick test and the 
ImmunoCAP ISAC test showed similar results for the other 
aeroallergens tested. Thus, specific IgE quantification with 
the ImmunoCAP ISAC test is of interest for asthma severity 
diagnosis only according to dust mite sensitization.
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